- Home
- BIOA vs LRMR Comparison
BIOA vs LRMR Comparison
Compare BIOA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BIOA | LRMR |
|---|---|---|
| Founded | 2015 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.0M | 455.8M |
| IPO Year | 2024 | 2014 |
Fundamental Metrics
Financial Performance| Metric | BIOA | LRMR |
|---|---|---|
| Price | $10.46 | $4.07 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 6 | 6 |
| Target Price | ★ $51.50 | $16.50 |
| AVG Volume (30 Days) | ★ 1.3M | 1.2M |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 66.21 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $8,995,000.00 | N/A |
| Revenue This Year | $720.93 | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.39 | $2.72 |
| 52 Week High | $25.96 | $6.42 |
Technical Indicators
Market Signals| Indicator | BIOA | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 30.99 | 52.90 |
| Support Level | $7.95 | $2.98 |
| Resistance Level | $13.17 | $4.21 |
| Average True Range (ATR) | 1.04 | 0.23 |
| MACD | -0.25 | 0.01 |
| Stochastic Oscillator | 10.27 | 58.96 |
Price Performance
Historical ComparisonAbout BIOA BioAge Labs Inc.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging. The company's technology platform and differentiated human datasets enable the identification of targets based on insights into molecular changes that drive aging. The Company operates and manages its business as one reportable and operating segment, which is the business of extending healthy human life by targeting molecular causes of aging.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.